Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viral CTLs for Refractory ADV or CMV Infection Post-HSCT
NCT07225972Phase 3Recruiting
- Sponsor
- New York Medical College
- Start
- Sep 2026
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in adenovirus infection and cytomegalovirus infection (CMV) (2 arms), sponsored by New York Medical College. Primary endpoint: Viral PCR to determine resolution of disease at Day 100. Started Sep 2026; status: recruiting.
02
Conditions
adenovirus infectioncytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT07225972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07225972.